News Kelun-Biotech first to bag TROP2 approval in lung cancer Kelun-Biotech wins first global regulatory approval - in China - for a TROP2-directed antibody-drug conjugate (ADC) in lung cancer.
News Boehringer eyes third quarter FDA verdict for oral HER2 drug Boehringer Ingelheim's oral HER2 inhibitor zongertinib has started an FDA review as a lung cancer treatment with a decision due in the third quarter.
News J&J says Rybrevant combo has survival edge over Tagrisso Rybrevant plus Lazcluze extended median OS by more than a year compared to Tagrisso in the MARIPOSA trial in treatment-naive, EGFR-mutated NSCLC.
News Daiichi and AZ pull Dato-DXd filing in Europe too AstraZeneca and Daiichi Sankyo have decided to voluntarily withdraw their EU marketing application for Dato-DXd in lung cancer.
News AZ gets EU okay for Tagrisso in early-stage lung cancer AstraZeneca's EGFR inhibitor Tagrisso has become the first drug in the class to be approved in the EU for a form of early-stage lung cancer.
News FDA dents J&J's blockbuster hopes for Rybrevant FDA has sent a complete response letter to J&J, denying approval of its subcutaneous version of lung cancer therapy Rybrevant.
News FDA chooses flu vaccine strains despite cancelled meeting The FDA has released its recommendations on the composition of influenza vaccines for the 2025-26 season – without the input of its external advisors.
Sales & Marketing Sponsored Health Trends 2025: Reimagining What's Possible Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl
